Clinical trials
Relapsed or Refractory Large B-cell Lymphoma clinical trials
Below are recruiting relapsed or refractory large b-cell lymphoma clinical trials, each written for real people, not researchers. We’re tracking 1,751 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05260957RecruitingPhase 2
CAR-T, mosunetuzumab, and polatuzumab for hard-to-treat lymphoma
This Phase 2 trial tests a combination approach to treat certain aggressive, relapsed, or refractory non-Hodgkin lymphomas. It may help by using CAR-T cells (a patient-specific immune treatment) along with other lymphoma medicines to shrink or control the cancer.
Miami, FloridaAges 18–80 - NCT06712810RecruitingPhase 1
Q702 for blood cancers and histiocytic disorders
This study tests an experimental pill called Q702 for people with certain blood cancers and related disorders (like histiocytoses, myelofibrosis, and lymphomas) that have not responded to standard treatments. It aims to see if Q702 is safe and effective.
Scottsdale, ArizonaAges 18 years+ - NCT05947851RecruitingPhase 3
Nemtabrutinib plus venetoclax versus standard add-on therapy
This Phase 3 study tests whether adding nemtabrutinib to venetoclax works better than the usual next treatment approach (venetoclax plus rituximab) in people with relapsed or treatment-resistant CLL/SLL. It may help by improving how well the cancer responds after at least one prior therapy.
Springdale, ArkansasAges 18 years+ - NCT03937544RecruitingPhase 2/Phase 3
Study of your own CAR-T cells for hard-to-treat B-ALL
This trial tests a treatment made from your own immune cells (CAR-T cells) to help control relapsed or refractory B-ALL. It is designed for people whose disease has come back or not responded to prior therapy, and who have specific brain/spinal fluid and organ health requirements.
Bandar Tun Razak, Kuala LumpurAges 13–65 - NCT05255354Recruiting
Testing blood cancer DNA monitoring during CAR-T treatment
This trial checks whether a blood test that looks for small amounts of cancer DNA can accurately track minimal residual disease (MRD) in lymphoma patients during CAR-T therapy. It may help doctors detect relapse earlier and better judge how well CAR-T is working.
Palo Alto, CaliforniaAges 18 years+ - NCT05312801RecruitingPhase 1
Testing BAFF CAR-T for relapsed or resistant non-Hodgkin lymphoma
This Phase 1 study tests a new immune cell treatment (BAFF CAR-T) for people with non-Hodgkin lymphoma that has come back or did not respond well to treatment. It aims to see how safe it is and whether it can help control the lymphoma.
Cleveland, OhioAges 18 years+ - NCT05529069RecruitingPhase 2
Testing pirtobrutinib plus venetoclax for relapsed mantle cell lymphoma
This Phase 2 trial tests how well the combination of pirtobrutinib and venetoclax works for people with mantle cell lymphoma that has come back or did not respond to treatment. It’s meant to help shrink the lymphoma and improve outcomes after prior therapies.
Houston, TexasAges 18 years+ - NCT06547528RecruitingPhase 1
Testing ONO-4685 for T cell lymphoma and CLL/SLL
This trial tests a new drug, ONO-4685, for people with certain types of T cell lymphoma or chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) that has not responded to standard treatments or cannot tolerate them. The goal is to see if the drug is safe and tolerable.
Nagoya, Aichi-kenAges 18 years+ - NCT06914037RecruitingPhase 1
CHT101 for CD70-positive blood cancers
This trial tests a new drug, CHT101, for people with certain blood cancers that have not responded to prior treatments. It is specifically for cancers that test positive for a protein called CD70.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT06976437RecruitingEarly Phase 1
Testing donor CAR-T cells for B-cell blood cancers
This trial tests a new treatment using specially engineered immune cells from a healthy donor to fight certain B-cell blood cancers that have come back or not responded to standard therapy. It aims to see if these cells can safely help patients achieve remission.
Zhenjiang, JiangsuAges 18 years+ - NCT03226704Enrolling by invitation
Leukapheresis to prepare CAR cell therapy
This trial collects white blood cells through a procedure called leukapheresis to help make CAR or other adoptive cell therapies. It’s for people with certain cancers who are not in remission (or are at high risk of relapse) and can meet health and lab requirements.
Bethesda, MarylandAges 3–65 - NCT07513129RecruitingPhase 1
New drug combination for relapsed T-cell blood cancer in teens and young adults
This trial tests a combination of four drugs (venetoclax, dexamethasone, bortezomib, and daratumumab) to treat T-cell acute lymphoblastic leukemia or lymphoma that has come back or stopped responding to prior treatment. The goal is to see if this combination can help patients aged 12–30 achieve remission.
Houston, TexasAges 12–30 - NCT04871607RecruitingPhase 2
Yttrium antibody plus chemotherapy for hard-to-treat Hodgkin lymphoma
This trial studies a targeted antibody therapy with yttrium, combined with intensive chemotherapy, for adults whose Hodgkin lymphoma did not respond well or came back. It may help by delivering cancer-killing radiation directly to lymphoma cells and preparing the body for treatment after transplant conditioning.
Duarte, CaliforniaAges 18 years+ - NCT06793956RecruitingPhase 1
Testing sintilimab and linperlisib for NK/T-cell lymphoma
This trial tests a combination of two drugs, sintilimab (immunotherapy) and linperlisib (targeted therapy), for people whose NK/T-cell lymphoma has come back or did not respond to previous treatment. The goal is to see if this combination can help shrink or control the cancer.
Guangzhou, GuangdongAges 18 years+ - NCT07271121RecruitingPhase 2
CAR T cells for CD19+ aggressive lymphoma
This trial tests a personalized treatment where your own immune cells are modified to find and kill lymphoma cells that have a protein called CD19. It may be an option if your lymphoma has returned or not responded to standard treatments.
AmmanAges 18–75 - NCT04586478RecruitingPhase 2
CNCT19 cell therapy for relapsed or resistant non-Hodgkin lymphoma
This Phase 2 trial tests whether an injected cell therapy called CNCT19 can treat non-Hodgkin lymphoma that has come back or did not respond to prior treatment. It may help by targeting specific lymphoma cells, but you must meet several safety and medical eligibility checks.
Beijing, Beijing MunicipalityAges 18–75 - NCT05868395RecruitingPhase 2
Treating relapsed mantle cell lymphoma with three drug combination
This Phase 2 study tests how well polatuzumab combined with bendamustine and rituximab works for mantle cell lymphoma that has come back or not responded. It may help shrink tumors and improve disease control, especially after prior treatment with ibrutinib.
ViennaAges 18–100 - NCT06054776RecruitingPhase 2
Acalabrutinib, obinutuzumab, and glofitamab for mantle cell lymphoma
This trial tests a combination of three targeted drugs for mantle cell lymphoma that has come back or not responded to prior treatment. It aims to see if this new drug cocktail can work better than standard options.
Duarte, CaliforniaAges 18 years+ - NCT06058858Recruiting
CMV reactivation after CAR-T cell therapy for leukemia or lymphoma
This study looks at how often a common virus called CMV reactivates—meaning it becomes active again—in patients who receive CAR-T cell treatment for leukemia or lymphoma. It aims to understand the risks and help doctors better manage care.
ParisAges 1–100 - NCT06224049RecruitingEarly Phase 1
New immune cells for Epstein-Barr virus positive T-cell lymphoma
This trial tests a new treatment using specially designed immune cells (called hNeo-T cells) to attack Epstein-Barr virus positive T-cell lymphoma that has come back or not responded to standard therapy. The treatment is personalized based on your tumor's unique markers and your tissue type (HLA).
Shenzhen, GuangdongAges 18–75 - NCT06252675RecruitingPhase 2
Glofitamab and pirtobrutinib for relapsed mantle cell lymphoma
This study tests a combination of two drugs—glofitamab (given as an infusion) and pirtobrutinib (a pill)—for people with mantle cell lymphoma that has come back or not responded to previous treatment. The goal is to see if the combo works better than either drug alone.
Davis, CaliforniaAges 18 years+ - NCT06776952RecruitingPhase 3
Study of XNW5004 for relapsed or refractory peripheral T-cell lymphoma
This study tests a new oral tablet called XNW5004 for people with peripheral T-cell lymphoma (a type of blood cancer) that has come back or not responded to prior treatments. The goal is to see if this drug can help shrink tumors or slow the disease.
Beijing, Beijing MunicipalityAges 3 weeks–2 months - NCT06850285Recruiting
CD30 CAR-T for relapsed or refractory CD30+ lymphoma
This trial tests a new type of immunotherapy called CD30 CAR-T cells for people with CD30-positive lymphoma that has come back or hasn't responded to other treatments. The treatment uses your own immune cells that are specially trained to find and kill lymphoma cells carrying the CD30 marker.
Taiyuan, ShangxiAges 15–80 - NCT06866873Recruiting
CAR-T cell therapy for kids with ALL or lymphoma
This trial tests a special immune cell treatment (CAR-T cells) for children whose leukemia or lymphoma has come back or not responded to at least two prior treatments. The goal is to see if these cells can find and destroy the cancer.
Hong KongAges 1–17
Hear when a new Relapsed or Refractory Large B-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapsed or refractory large b-cell lymphoma?
- Yes. Clin2 currently lists 1,751 recruiting relapsed or refractory large b-cell lymphoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed or refractory large b-cell lymphoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed or refractory large b-cell lymphoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Relapsed/Refractory Large B-Cell Lymphoma
- Refractory Diffuse Large B-Cell Lymphoma
- Refractory Primary Mediastinal Large B-Cell Lymphoma
- Diffuse Large B Cell Lymphoma Relapsed
- Relapsed/Refractory B-cell Lymphoma
- Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
- Relapsed or Refractory B-cell Lymphoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.